en · de · es · fr · pt
ipamorelin-notes.peptides7501.com › Topic › Ipamorelin Background And Mechanism — Background and Details

Ipamorelin Background And Mechanism — Background and Details

By Editorial Desk · published 2025-10-19 · last reviewed 2025-12-09 · Topic

A practical reference on GHS-R1a: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2025-12-09 and is reviewed periodically as new material appears.

Ipamorelin Background and Mechanism

Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.

Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.

Handling Storage And Analytical Control

Research peptides such as ipamorelin are commonly supplied as lyophilized powder and characterized by analytical certificates. Reversed-phase high-performance liquid chromatography is used to estimate purity by ultraviolet absorbance, while mass spectrometry confirms molecular identity and detects sequence-related impurities. Counterion content, water content, and residual synthesis reagents can affect the reported mass balance. A certificate of analysis may list a purity percentage, but that number depends on the analytical method and the definition of impurity peaks. Independent verification is often recommended because research supply chains vary in quality control practices.

Storage recommendations for ipamorelin usually focus on temperature, moisture, and light. Lyophilized powder is typically held at or below minus twenty degrees Celsius in a desiccated container protected from light. Reconstituted solutions are often aliquoted and stored at minus eighty degrees Celsius to reduce repeated freeze-thaw cycles, which can promote aggregation or degradation. The optimal buffer and pH depend on the specific assay, and no single condition applies to every experimental context. Peptide stability should be assessed with time-point measurements rather than assumed from general handling rules.

Ipamorelin at a glance

PropertyValueNotes
Molecular formulaC38H49N9O5Includes two non-natural residues
Molecular weightAbout 711.9 g/molConfirmed by mass spectrometry
AppearanceWhite to off-white powderTypical lyophilized form
Receptor targetGHS-R1aGhrelin receptor agonist
Plasma half-lifeRoughly 2 hoursVaries by species and assay

分析检测与储存稳定性

杂质谱一般包含缺失序列片段、差向异构体、氧化产物以及残留溶剂或反离子,其中组氨酸与芳香残基的氧化常被重点关注。反相色谱中这类杂质往往紧邻主峰洗脱,因此方法需要足够的分离度并经过系统适用性验证。纯度百分比的解读依赖于检测波长与梯度条件,不同实验室公布的数字不宜直接横向比较。参考标准品有助于跨批次对照,但其自身赋值同样需要可追溯来源。

冻干状态下的肽通常比溶液状态更稳定,常规做法是维持 -20 °C 或更低温度、保持干燥并避开强光。复溶后的降解主要来自水解、氧化与脱酰胺,速率受 pH、缓冲液种类、离子强度与温度共同影响,碱性条件一般会加快这些反应。反复冻融会造成聚集与容器吸附损失,分装保存能降低该风险。容器材质与金属离子也可能参与氧化过程,需与操作条件一并考虑。

对 ipamorelin 的常规表征以反相高效液相色谱测定纯度,检测波长多设为 214 nm,因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱,将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来,可以分别覆盖纯度、身份与序列三个不同层次的信息。

Related pages on this site

Handling, Storage, and Analytical Characterization

Analytical confirmation relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry for identity and purity assessment. Mass spectrometry distinguishes the intact molecule from truncation products and from oxidation or deamidation variants that share similar chromatographic retention. Immunoassays appear in some biological studies but can cross-react with related peptides, so they are weaker tools for identity work. Reported purity figures depend heavily on the gradient, detector, and integration method used, which complicates direct comparison between laboratories.

Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.

Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.

背景与分子特征

从用途定位看,ipamorelin 目前主要以研究用肽的身份被讨论,未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用,不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小,因此对其效应强度与一致性的描述应保持谨慎。

Ipamorelin 是一种合成五肽,序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2,分子式 C38H49N9O5,游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素(GHS)家族,作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道,设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。

Ipamorelin Background and Receptor Pharmacology

Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.

In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.

Notes from published material

In addition to its role as a natural hormone, estradiol is used as a medication, for instance in menopausal hormone therapy, and feminizing hormone therapy for transgender women and some genderqueer individuals; for information on estradiol as a medication, see the estradiol (medication) article.

==== 1920s–1930s ==== Following the passage of the Second International Opium Convention in 1925, which specifically banned morphine and the diacetyl ester of morphine, heroin, a number of alternative esters of morphine quickly started to be manufactured and sold. The most notable of these were dibenzoylmorphine and acetylpropionylmorphine, which have virtually identical effects to heroin but were not covered by the Opium Convention. This then led the Health Committee of the League of Nations to pass several resolutions attempting to bring these new drugs under control, ultimately leading in 1930 to the first broad analogues provisions extending legal control to all esters of morphine, oxycodone and hydromorphone. Another early example of what could loosely be termed designer drug use, was during the Prohibition era in the 1930s, when diethyl ether was sold and used as an alternative to illegal alcoholic beverages in a number of countries.

The Calvin cycle, also known as the dark reactions, is a series of biochemical reactions that fixes CO2 into G3P sugar molecules and uses the energy and electrons from the ATP and NADPH made in the light reactions. The Calvin cycle takes place in the stroma of the chloroplast. While named "the dark reactions", in most plants, they take place in the light, since the dark reactions are dependent on the products of the light reactions.

Sources: en.wikipedia.org

Background from the literature

== Structural Chemistry == Caricain is synthesized as a preproenzyme. There is evidence at the mRNA level for polymorphism, two very similar clones being isolated, one of which contained a C-terminal extension. The primary structure of the mature form of the enzyme has been determined, and is as predicted from one of the cDNA sequences. The protein is 216 amino acids in length, and is 68% identical in sequence to papain, 65% to chymopapain and 81% to glycyl endopeptidase. The three disulfide bonds are conserved between all the papaya proteinases, and there is no evidence for glycosylation. Caricain is an extremely basic protein, with pI estimated to be 11.7. The A280,1% is reported to be 18.3, giving a molar extinction coefficient of 4.193 104 M21 cm21. As with some other plant cysteine endopeptidases, caricain exhibits charge heterogeneity. This may be partly due to variation in the oxidization state of the active-site sulfur, as is the case with homologous enzymes from pineapple stem, although genetic polymorphism may also contribute. The crystal structure of caricain has been solved to a resolution of 1.8 A ̊, and demonstrates main-chain conformation very similar to that of papain. Caricain has four amino acid residues (Ser169-Lys172) not present in papain, but it is papain that is exceptional at this point in the sequence, showing a deletion not seen in other members of the family. The architecture of the active site of caricain is very similar to that of papain.

For a compound to reach a tissue, it usually must be taken into the bloodstream – often via mucous surfaces like the digestive tract (intestinal absorption) – before being taken up by the target cells. Factors such as poor compound solubility, gastric emptying time, intestinal transit time, chemical instability in the stomach, and inability to permeate the intestinal wall can all reduce the extent to which a drug is absorbed after oral administration. Absorption critically determines the compound's bioavailability. Drugs that absorb poorly when taken orally must be administered in some less desirable way, like intravenously or by inhalation (e.g. zanamivir). Routes of administration are an important consideration.

Note that most commonly used lac or lac-derived promoters are based on the lacUV5 mutant which is insensitive to catabolite repression. This mutant allows for expression of protein under the control of the lac promoter when the growth medium contains glucose since glucose would inhibit gene expression if wild-type lac promoter is used. Presence of glucose nevertheless may still be used to reduce background expression through residual inhibition in some systems. Examples of E. coli expression vectors are the pGEX series of vectors where glutathione S-transferase is used as a fusion partner and gene expression is under the control of the tac promoter, and the pET series of vectors which uses a T7 promoter. It is possible to simultaneously express two or more different proteins in E. coli using different plasmids. However, when 2 or more plasmids are used, each plasmid needs to use a different antibiotic selection as well as a different origin of replication, otherwise one of the plasmids may not be stably maintained. Many commonly used plasmids are based on the ColE1 replicon and are therefore incompatible with each other; in order for a ColE1-based plasmid to coexist with another in the same cell, the other would need to be of a different replicon, e.g. a p15A replicon-based plasmid such as the pACYC series of plasmids. Another approach would be to use a single two-cistron vector or design the coding sequences in tandem as a bi- or poly-cistronic construct.

Blood plasma fractionation are the general processes separating the various components of blood plasma, which in turn is a component of blood obtained through blood fractionation. Plasma-derived immunoglobulins are giving a new narrative to healthcare across a wide range of autoimmune inflammatory diseases.

Sources: en.wikipedia.org

Further detail

== Non-inertial frame of reference == The rotating frame of reference introduces some interesting pseudo-forces into the equations through the material derivative term. Consider a stationary inertial frame of reference

==== Branding irons ==== Freeze brands are distinct from hot branding irons, which are generally made from steel or cast iron. Freeze brands at their working temperature possess a smaller difference in temperature from 25 °C than hot brands (−72 °C to −196 °C vs +500 °C). They must therefore be applied for much longer durations—up to 1 minute, compared to 3–5 seconds for hot branding. Further, the rapid removal of heat fundamentally differs from the sudden addition of heat, both in its physiological effects and the time required to achieve a given change in temperature. To compensate for these disadvantages the thermal conductivity of the brand is far more important in freeze branding than it is in hot branding. Freeze brands are occasionally made from pure copper but are more often made of a cupronickel alloy. This alloy was selected to exploit copper's high thermal conductivity (only diamond and silver are better heat conductors) and nickel's ability to extend copper's high thermal conductivity into cryogenic temperature regimes. Maximum thermal conductivity is desirable because it directly controls how long the supercooled iron must be pressed to the animal's skin. For this reason, steel, brass, bronze and aluminum cryogenic brands are no longer widely used. Commercial freeze brands generally have a stamp on the stem end indicating what shape of the brand will be produced. This allows the user to select the right brand from the coolant bath without lifting each out to inspect its face.

== History == Hypoglycemia was first recognized in the 19th century. In the 1920s, after the discovery of insulin and its use in the treatment of diabetics, hyperinsulinism was suspected to be a cause of hypoglycemia in nondiabetics. A pioneering description of hyperinsulinism as a cause of hypoglycemia was published by Seale Harris in 1924. The first report of a surgical cure of hypoglycemia by removing an islet cell tumour was in 1929. An insulinoma removed from a woman in Munich provided insulin mRNA that was used in the first human gene cloning experiment. In 1979, Axel Ullrich cloned this gene into E. coli. Most therapeutic insulin used today derives from this woman's tumour.

== History == George W. Corner and Willard M. Allen discovered the hormonal action of progesterone in 1929. By 1931–1932, nearly pure crystalline material of high progestational activity had been isolated from the corpus luteum of animals; by 1934, pure crystalline progesterone had been refined and obtained, and the chemical structure of progesterone was determined. This was achieved by Adolf Butenandt at the Chemisches Institut of Gdańsk Technical University in Danzig, who extracted this new compound from several thousand liters of urine. Chemical synthesis of progesterone from stigmasterol and pregnanediol was accomplished later that year. Up to this point, progesterone, known generically as corpus luteum hormone, had been being referred to by several groups by different names, including corporin, lutein, luteosterone, and progestin. In 1935, at the time of the Second International Conference on the Standardization of Sex Hormones in London, England, a compromise was reached between the groups, and the name 'progesterone' (progestational steroidal ketone) was created.

== Origin == The term was coined by Joseph Marius DallaValle in his book Micromeritics: The Technology of Fine Particles (1948). It was derived from the Greek words Greek: μικρο, romanized: micro meaning "small" and Greek: μέρος, romanized: méros meaning "part". The size range which he covered in the book was from 100 nm to 100 mm. Anything smaller than this but bigger than a molecule was referred to at the time as a colloid but is now often referred to as a nanoparticle. Applications included soil physics, mineral physics, chemical engineering, geology, and hydrology. Characteristics discussed included particle size and shape, packing, electrical, optical, chemical and surface science.

Sources: en.wikipedia.org

Frequently asked questions

What is the amino acid sequence of ipamorelin?

The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.

How does ipamorelin differ from earlier growth hormone secretagogues?

It binds the same ghrelin receptor but with greater selectivity in functional assays. Preclinical work reports less cortisol and prolactin stimulation at growth-hormone-releasing doses. Those differences are relative, not absolute, and depend on dose and model.

Is ipamorelin an approved medicine?

No major regulatory authority has approved it for human therapeutic use. It is sold as a research chemical for laboratory investigation. Clinical status varies by country and is subject to change.

How is ipamorelin purity measured?

Purity is commonly estimated by reversed-phase high-performance liquid chromatography with ultraviolet detection. Mass spectrometry is used to confirm identity and to detect sequence-related impurities. Reported percentages depend on the method and the impurity threshold used.

Network